Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 86 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 1.7 mo · strongest signal: MVLS deficiency (Aug 28, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 175 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 14, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-09-14 filing | 30 |
| Sep 3, 2026 | ▼ Shelf effective | EFFECT notice 2026-09-03 filing | 21 |
| Aug 28, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (EX-4.2) filed 2026-08-28 filing | 51 |
| Aug 28, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-4.1) filed 2026-08-28 filing | 45 |
| Aug 28, 2026 | ▼ ATM program | “atm” language in 8-K (EX-4.1) filed 2026-08-28 filing | 40 |
| Aug 28, 2026 | ▼ Convertible note | “convertible note” language in 8-K (EX-4.1) filed 2026-08-28 filing | 39 |
| Aug 28, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-10.2) filed 2026-08-28 filing | 38 |
| Aug 28, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-28 (accepted 17:23 ET) filing | 35 |
| Aug 28, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.2) filed 2026-08-28 filing | 35 |
| Aug 28, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-4.1) filed 2026-08-28 filing | 32 |
| Aug 28, 2026 | ▼ Shelf filed | S-1 filed 2026-08-28 filing | 31 |
| Aug 28, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-08-28 (accepted 17:23 ET) filing | 30 |
| Aug 28, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-08-28 (accepted 17:23 ET) filing | 30 |
| Aug 28, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-08-28 filing | 30 |
| Aug 28, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-08-28 (accepted 17:23 ET) filing | 30 |
| Mar 31, 2026 | ▼ Runway < 6 months | ~1.7 months runway: liquidity $2,563,000 as of 2026-03-31, burn $18,183,453/yr (annualized 181-day YTD operating cash flow [companyfacts]) filing | 36 |
| Mar 31, 2026 | ▼ Cash < current liabilities | Liquidity $2,563,000 vs current liabilities $24,026,000 filing | 22 |
DAIC CID Holdco, Inc. · SDST Stardust Power Inc. · ISPC iSpecimen Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · BRTX BioRestorative Therapies, In · screener →